Form 4: Confluent CEO Sells 232,500 Shares Under 10b5-1 Plan

Sentiment:

Insider Transaction Report


Confluent CEO Edward Kreps reported the sale of 232,500 Class A Common Stock shares for an average price of $23.53, executed under a pre-arranged 10b5-1 trading plan.

Summary

  • Edward Jay Kreps, Confluent's Chief Executive Officer and a Director, reported a change in beneficial ownership.
  • On November 13, 2025, Kreps converted 232,500 shares of Class B Common Stock into Class A Common Stock.
  • Simultaneously, 232,500 shares of Class A Common Stock were sold at an average price of $23.53 per share.
  • The sales occurred within a price range of $23.23 to $24.19 per share.
  • The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 15, 2024.
  • Following these transactions, Kreps directly beneficially owns 377,074 shares of Class A Common Stock.
  • Kreps also indirectly holds 14,482,500 shares of Class B Common Stock through various trusts.

Sentiment

Score: 4

Explanation: The sentiment is slightly cautious due to insider selling by the CEO, although the execution under a pre-planned 10b5-1 trading plan mitigates significant negative implications, suggesting a routine liquidity event rather than a lack of confidence.

Positives

  • The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to recent negative company performance or outlook, which provides transparency and reduces the likelihood of insider trading allegations.

Negatives

  • The sale of a significant number of shares (232,500) by a key executive like the CEO could be perceived by some investors as a lack of confidence in the company's future prospects, even if pre-planned.

Risks

  • Investor perception of insider selling, even when pre-planned, can sometimes lead to negative sentiment or speculation regarding the company's future performance.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

  • Indirect beneficial ownership of Class B Common Stock is held through The Edward J. Kreps and Jamaica H. Kreps 2018 Revocable Trust, and the GST Exempt Trust under The Kreps Family 2019 Irrevocable Trust, which are related party entities.

Stakeholder Impact

  • Shareholders may interpret the insider sale with caution, though the 10b5-1 plan context suggests it is a pre-planned financial management action rather than a signal of immediate company distress.

Next Steps

  • The reporting person will provide full information regarding the number of shares sold at each separate price within the reported range to the SEC, the issuer, or any security holder upon request.

Key Dates

DateDescription
08/15/2024Date the Rule 10b5-1 trading plan was adopted.
11/13/2025Date of the reported conversion and sale transactions.
11/17/2025Date the Form 4 filing was signed.

Recommendation

hold

The sale by Confluent's CEO, Edward Kreps, was conducted under a pre-arranged 10b5-1 trading plan. Such plans are typically set up in advance for personal financial planning and do not necessarily reflect a change in management's outlook on the company's future performance. While insider selling can sometimes be a negative signal, the pre-planned nature of this transaction reduces its immediate significance as an indicator of company health. Therefore, a 'hold' recommendation is appropriate, as this single transaction does not provide sufficient new information to alter the fundamental investment thesis for Confluent.

Keywords

Confluent, CFLT, Edward Kreps, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Class A Common Stock, Class B Common Stock

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.